Feedback / Questions
ampreloxetine (TD-9855) - Theravance Biopharma
https://www.prnewswire.com/news-releases/theravance-biopharma-completes-enrollment-in-pivotal-phase-3-cypress-study-of-ampreloxetine-in-patients-with-symptomatic-neurogenic-orthostatic-hypotension-due-to-multiple-system-atrophy-302537380.html
Aug 25, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next